Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 5.1 Opinion of Ropes & Gray LLP
- 23.1 Consent of Ernst & Young LLP
- 23.2 Consent of Ernst & Young LLP
- 23.4 Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
- 23.5 Consent of Harris Nesbitt Corp.
- 99.4 Consent of Merrill Lynch, Pierce, Fenner & Smith Incorporated
- 99.5 Form of Genome Therapeutics Corp. Proxy Card
- 99.6 Form of Genesoft Pharmaceuticals, Inc. Proxy Card
- 99.9 Consent of David B. Singer
- 99.10 Consent of Luke B. Evnin
- 99.11 Consent of William J. Rutter
- 99.12 Consent of Vernon R. Loucks, JR.
OSCI similar filings
- 10 Sep 08 Registration of securities issued in business combination transactions
- 15 Mar 07 Registration of securities issued in business combination transactions
- 30 Dec 03 Registration of securities issued in business combination transactions (amended)
- 15 Dec 03 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 23.2
Consent of ERNST & YOUNG LLP, Independent Auditors
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated April 28, 2003 except for Note 12 as to which the date is November 17, 2003, included in the Proxy Statement of Genesoft Pharmaceuticals, Inc. that is made a part of Amendment No. 1 to the Registration Statement (Form S-4) and Prospectus of Genome Therapeutics Corp. for the registration of shares of its common stock.
/s/ ERNST & YOUNG LLP
Palo Alto, California
December 29, 2003